Related Experiment Videos
Atypical neuroleptics and diabetes
S Béliard1, R Valero, B Vialettes
1Service de Nutrition, Maladies métaboliques, Endocrinologie, Hôpital de Sainte Marguerite, Marseille, France. bvialettes@mail.ap-hm.fr
Diabetes & Metabolism
|August 12, 2003
Summary
Atypical antipsychotics like clozapine and olanzapine can worsen diabetes. Close monitoring of weight, glucose, and lipids is crucial for patients on these medications to prevent metabolic issues.
Area of Science:
- Endocrinology
- Psychiatry
- Pharmacology
Background:
- Atypical antipsychotics are increasingly linked to diabetes mellitus.
- Limited information exists for diabetologists regarding this association.
- This study addresses the metabolic complications of these drugs.
Observation:
- Two cases of severe diabetes deterioration in patients treated with clozapine and olanzapine are presented.
- These cases highlight the significant impact of specific atypical antipsychotics on glucose metabolism.
Findings:
- A literature review supports the link between atypical antipsychotics and diabetes.
- Potential mechanisms contributing to neuroleptic-associated diabetes are discussed.
- Both clozapine and olanzapine were implicated in the observed cases.
Implications:
- Healthcare providers should closely monitor weight, glycemic, and lipid parameters in patients on atypical antipsychotics.
- Early detection and intervention are key to managing metabolic complications.
- This emphasizes the need for collaborative care between psychiatric and endocrine specialists.